Cure My Disease

Don't miss your cure!

 Log in / Sign up

Immune cells engineered to hunt viruses show promise for transplant kids

NCT ID NCT07685457

Recruiting now Disease control Sponsor: LucasBio Source: ClinicalTrials.gov ↗

First seen Jul 06, 2026 · Last updated Jul 07, 2026 · Updated 1 time

Summary

This study tests a new cell therapy called LB-DTK-MV in children aged 1-25 who have stubborn viral infections (CMV, EBV, or BKV) after a stem cell transplant. The therapy uses specially grown immune cells from a donor to attack the viruses. Participants receive two infusions two weeks apart and are monitored for side effects, viral levels, and symptom improvement over six months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
LB-DTK-MV (virus-specific T cells)
What this could lead to
If successful, this could offer a new treatment option for children with stubborn viral infections after a stem cell transplant, potentially reducing the need for other antiviral drugs.
What could go wrong
This is a very small, early-stage trial with only 6 participants, so results may not apply to everyone. The therapy may cause side effects or fail to control the infection.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BKV INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

BK-virus nephropathy cytomegalovirus infection Epstein-Barr virus infection Infections

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BKV INFECTION CMV INFECTION EBV INFECTION

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • The Catholic University of Korea Seoul St.Mary's Hospital

    RECRUITING

    Seoul, 06591, South Korea

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.